Physician profile

Asit Bhatt

Obstetrics & Gynecology · Albuquerque, NM

NPI 1184839854

$3,416.98

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$34.60

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Boston Scientific Corporation $1,253.66 2022
Asensus Surgical, INC. $920.51 2019
Acessa Health INC. $829.96 2019
Caldera Medical, INC $131.98 2019
Pacira Pharmaceuticals Incorporated $121.80 2019
Intuitive Surgical, INC. $86.11 2019
Abbvie INC. $22.13 2022
Coopersurgical, INC. $17.38 2023 Paragard T 380a
Organon LLC $17.22 2023 Nexplanon
Bayer Healthcare Pharmaceuticals INC. $16.23 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Asit Bhatt

$3,416.98

in general payments reported 2019-2025

Years
2019-2023
Top company
Boston Scientific Corporation

https://glasscript.com/doctor/54106/asit-bhatt

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.